Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Gilead may be entertaining acquisition of Arcus, says Cantor Fitzgerald » 07:30
04/16/20
04/16
07:30
04/16/20
07:30
RCUS

Arcus Biosciences

$15.57 /

-0.95 (-5.75%)

, GILD

Gilead

$74.60 /

-3.09 (-3.98%)

, FTSV

Forty Seven

$0.00 /

+ (+0.00%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Alethia Young says Bloomberg's headline that Gilead (GILD) is in talks to buy a stake in Arcus Biosciences (RCUS) "doesn't strike us as surprising," telling investors in a research note that there are many relevant proof-of-concept readouts for Arcus in both its adenosine antagonist and its anti-TIGIT and that Gilead is likely acquiring many more assets beyond Forty Seven (FTSV) in oncology. The analyst adds that Gilead is likely entertaining an acquisition of Arcus, and that potentially others could be serious about a deal. Her analysis suggests takeout valuations of $33-$45 for Arcus.

ShowHide Related Items >><<
RCUS Arcus Biosciences
$15.57 /

-0.95 (-5.75%)

04/16/20 BTIG
Arcus Biosciences price target raised to $34 from $20 at BTIG
04/16/20 Goldman Sachs
Gilead partnership with Arcus would fit within strategy, says Goldman Sachs
04/16/20 Mizuho
Arcus pipeline has upside with or without partner, says Mizuho
04/03/20
Fly Intel: Top five analyst initiations
GILD Gilead
$74.60 /

-3.09 (-3.98%)

04/13/20 JPMorgan
Gilead COVID-19 data offers 'promising first look,' says JPMorgan
FTSV Forty Seven
$0.00 /

+ (+0.00%)

03/04/20 Wells Fargo
Gilead price target raised to $87 from $81 at Wells Fargo
03/04/20 Mizuho
Forty Seven downgraded to Neutral from Buy at Mizuho
03/03/20 Guggenheim
Forty Seven downgraded to Neutral from Buy at Guggenheim
03/03/20 Canaccord
Forty Seven downgraded to Hold from Buy at Canaccord
Options
Two new option listings and one option delisting on April 8th » 08:30
04/08/20
04/08
08:30
04/08/20
08:30
FBK

FB Financial

$19.65 /

+0.08 (+0.41%)

, GFL

GFL Environmental

$13.28 /

+0.73 (+5.82%)

, FTSV

Forty Seven

$95.50 /

+ (+0.00%)

New option listings for…

New option listings for April 8th include FB Financial (FBK) and GFL Environmental Inc (GFL). Option delistings effective April 8th include Forty Seven Inc (FTSV).

ShowHide Related Items >><<
FBK FB Financial
$19.65 /

+0.08 (+0.41%)

01/02/20 SunTrust
SunTrust raises price targets on select regional banks on improved margins
12/09/19 Sandler O'Neill
FB Financial downgraded to Hold from Buy at Sandler O'Neill
10/23/19 Raymond James
FB Financial downgraded to Market Perform on valuation at Raymond James
10/23/19 Raymond James
FB Financial downgraded to Market Perform from Outperform at Raymond James
GFL GFL Environmental
$13.28 /

+0.73 (+5.82%)

03/31/20 BMO Capital
GFL Environmental initiated with an Outperform at BMO Capital
03/30/20 RBC Capital
GFL Environmental initiated with an Outperform at RBC Capital
03/30/20
Fly Intel: Top five analyst initiations
03/30/20 JPMorgan
GFL Environmental initiated with an Overweight at JPMorgan
FTSV Forty Seven
$95.50 /

+ (+0.00%)

03/04/20 Wells Fargo
Gilead price target raised to $87 from $81 at Wells Fargo
03/04/20 Mizuho
Forty Seven downgraded to Neutral from Buy at Mizuho
03/03/20 Guggenheim
Forty Seven downgraded to Neutral from Buy at Guggenheim
03/03/20 Canaccord
Forty Seven downgraded to Hold from Buy at Canaccord
Over a quarter ago
Earnings
Forty Seven reports Q4 EPS (61c), consensus (71c) » 16:02
03/20/20
03/20
16:02
03/20/20
16:02
FTSV

Forty Seven

$91.95 /

+0.45 (+0.49%)

"In 2019, Forty…

"In 2019, Forty Seven transformed into a multi-asset, late-stage development company with clear paths to registration in two distinct, underserved patient populations. In parallel, we entered into several new partnerships designed to accelerate the development of magrolimab and FSI-174, and allow us to evaluate both compounds more rapidly across a range of indications and combination paradigms," said Mark McCamish, M.D., Ph.D., President and CEO of Forty Seven. "Following the recently announced acquisition by Gilead, and with the benefit of their resources and capabilities, we are even better positioned to build on this momentum and deliver on our foundational vision of developing novel immunotherapies that help patients defeat their cancers." Dr. McCamish continued, "Like so many others, we are closely monitoring COVID-19, and have recently instituted a number of proactive measures to mitigate the spread of the virus and protect the safety, health and well-being of the patients, families and healthcare professionals involved in our clinical development programs, as well as our employees. While we are working diligently to limit the impact of COVID-19 on our ongoing clinical trials, we, together with our contract research organization, decided to delay the initiation of our Phase 1 trial of FSI-174 in healthy volunteers in order to support physicians and hospitals in devoting their resources to treating COVID-19 patients, and avoid exposing healthy volunteers to unnecessary risk. We will continue to evaluate the pandemic and expect to re-visit the timing of potential trial initiation in the second quarter."

ShowHide Related Items >><<
FTSV Forty Seven
$91.95 /

+0.45 (+0.49%)

03/04/20 Wells Fargo
Gilead price target raised to $87 from $81 at Wells Fargo
03/04/20 Mizuho
Forty Seven downgraded to Neutral from Buy at Mizuho
03/03/20 Guggenheim
Forty Seven downgraded to Neutral from Buy at Guggenheim
03/03/20 Canaccord
Forty Seven downgraded to Hold from Buy at Canaccord
Periodicals
Trillium could be 'compelling' target after Forty Seven deal, Dealreporter says » 09:42
03/11/20
03/11
09:42
03/11/20
09:42
TRIL

Trillium Therapeutics

$5.48 /

+ (+0.00%)

, FTSV

Forty Seven

$94.98 /

+ (+0.00%)

, GILD

Gilead

$72.35 /

+ (+0.00%)

Noting that the proxy…

Noting that the proxy filing made yesterday by Forty Seven (FTSV) suggests that Gilead (GILD) was competing with a mid-cap biotech for the company, Dealreporter said in a flash note to its subscribers that the "competitive counterbid...would seem to strengthen the case for Trillium Therapeutics (TRIL)....as a compelling takeout target," according to contacts. In early trading, Trillium shares are up about 4% to $5.66.

ShowHide Related Items >><<
TRIL Trillium Therapeutics
$5.48 /

+ (+0.00%)

08/19/19
Fly Intel: Top five analyst downgrades
08/19/19 H.C. Wainwright
Trillium Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
03/12/19 H.C. Wainwright
Trillium Therapeutics price target lowered to $4 from $10 at H.C. Wainwright
FTSV Forty Seven
$94.98 /

+ (+0.00%)

03/04/20 Wells Fargo
Gilead price target raised to $87 from $81 at Wells Fargo
03/04/20 Mizuho
Forty Seven downgraded to Neutral from Buy at Mizuho
03/03/20 Guggenheim
Forty Seven downgraded to Neutral from Buy at Guggenheim
03/03/20 Canaccord
Forty Seven downgraded to Hold from Buy at Canaccord
GILD Gilead
$72.35 /

+ (+0.00%)

03/09/20 RBC Capital
Gilead downgraded to Outperform from Top Pick at RBC Capital
03/09/20 RBC Capital
Gilead downgraded to Outperform from Top Pick at RBC Capital
Hot Stocks
Forty Seven, Rocket Pharmaceuticals announces research collaboration » 08:13
03/11/20
03/11
08:13
03/11/20
08:13
FTSV

Forty Seven

$94.98 /

+0.53 (+0.56%)

, RCKT

Rocket Pharmaceuticals

$18.19 /

+0.11 (+0.61%)

Forty Seven (FTSV) and…

Forty Seven (FTSV) and Rocket Pharmaceuticals (RCKT) announced that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven's novel antibody-based conditioning regimen, FSI-174 plus magrolimab, with Rocket's ex vivo lentiviral vector hematopoietic stem cell gene therapy, RP-L102. The initial collaboration will evaluate this treatment regimen in Fanconi Anemia, a genetic disease that affects patients' capacity to produce blood cells and is associated with an increased risk of leukemia and other neoplasms. RP-L102, Rocket's gene therapy approach for FA, involves treatment with patients' own gene-corrected blood forming stem cells. Gene therapies for monogenic blood disorders have broad potential. One concern associated with these treatments is the toxicity of pre-therapy conditioning regimens that utilize cytotoxic chemotherapy and/or radiation to destroy existing HSCs and facilitate engraftment of gene-corrected HSCs. Forty Seven's all-antibody based conditioning regimen is designed to address the limitations of current pre-treatment conditioning therapies. These regimens are often associated with serious side effects, including severe infection, cognitive impairment, infertility, endocrine dysfunction, secondary malignancies and organ damage. These toxicities are especially difficult for pediatric patients and are particularly severe for patients with FA, who are more sensitive to the DNA-damaging effects of traditional conditioning agents. Preliminary data demonstrate that RP-L102 may confer efficacy without pre-treatment conditioning. The combination of RP-L102 with Forty Seven's all-antibody conditioning regimen may provide patients an alternate treatment option in situations where conditioning may be advantageous. Under the terms of the agreement, Rocket will provide its ex vivo LVV HSC gene therapy platform and Forty Seven will contribute its innovative antibody-based conditioning regimen for the collaboration.

ShowHide Related Items >><<
FTSV Forty Seven
$94.98 /

+0.53 (+0.56%)

03/04/20 Wells Fargo
Gilead price target raised to $87 from $81 at Wells Fargo
03/04/20 Mizuho
Forty Seven downgraded to Neutral from Buy at Mizuho
03/03/20 Guggenheim
Forty Seven downgraded to Neutral from Buy at Guggenheim
03/03/20 Canaccord
Forty Seven downgraded to Hold from Buy at Canaccord
RCKT Rocket Pharmaceuticals
$18.19 /

+0.11 (+0.61%)

03/05/20 Piper Sandler
Piper sees 'substantial value' for Rocket from numerous trial readouts
12/09/19 Oppenheimer
Rocket Pharmaceuticals price target raised to $42 from $36 at Oppenheimer
12/06/19 Baird
Rocket Pharmaceuticals elevated to Fresh Pick, target raised to $41 at Baird
11/18/19 Piper Sandler
Rocket may be next leading lentiviral vector company, says Piper Jaffray
Recommendations
Gilead price target raised to $87 from $81 at Wells Fargo » 08:49
03/04/20
03/04
08:49
03/04/20
08:49
GILD

Gilead

$74.26 /

-1.14 (-1.51%)

, FTSV

Forty Seven

$94.21 /

+0.33 (+0.35%)

Wells Fargo analyst Jim…

Wells Fargo analyst Jim Birchenough raised the firm's price target on Gilead (GILD) to $87 from $81 and keeps an Overweight rating on the shares following recent outperformance and on assessment of potential remdesivir opportunity in addressing current coronavirus outbreak. Overall, the analyst believes incremental value can be justified, and see further upside potential on broader pipeline progress, new opportunity with Forty Seven (FTSV) acquisition and potential for additional deals.

ShowHide Related Items >><<
GILD Gilead
$74.26 /

-1.14 (-1.51%)

03/04/20 Mizuho
Forty Seven downgraded to Neutral from Buy at Mizuho
03/03/20 Canaccord
Forty Seven downgraded to Hold from Buy at Canaccord
03/02/20 H.C. Wainwright
Forty Seven downgraded to Neutral from Buy at H.C. Wainwright
03/02/20 Roth Capital
Forty Seven downgraded to Neutral from Buy at Roth Capital
FTSV Forty Seven
$94.21 /

+0.33 (+0.35%)

03/03/20 Guggenheim
Forty Seven downgraded to Neutral from Buy at Guggenheim
03/03/20 SunTrust
Forty Seven downgraded to Hold from Buy at SunTrust
Downgrade
Forty Seven downgraded to Neutral from Buy at Mizuho » 05:09
03/04/20
03/04
05:09
03/04/20
05:09
FTSV

Forty Seven

$94.21 /

+0.33 (+0.35%)

, GILD

Gilead

$74.26 /

-1.14 (-1.51%)

Mizuho analyst Mara…

Mizuho analyst Mara Goldstein downgraded Forty Seven (FTSV) to Neutral from Buy with a price target of $95.50, up from $53. As the company's bidding process was said to be competitive, a competing takeover to challenge the one from Gilead Sciences (GILD) is unlikely, Goldstein tells investors in a research note. The analyst downgraded Forty Seven to reflect the proposed takeout price.

ShowHide Related Items >><<
FTSV Forty Seven
$94.21 /

+0.33 (+0.35%)

03/03/20 Guggenheim
Forty Seven downgraded to Neutral from Buy at Guggenheim
03/03/20 Canaccord
Forty Seven downgraded to Hold from Buy at Canaccord
03/03/20 SunTrust
Forty Seven downgraded to Hold from Buy at SunTrust
03/03/20 Morgan Stanley
Forty Seven downgraded to Equal Weight from Overweight at Morgan Stanley
GILD Gilead
$74.26 /

-1.14 (-1.51%)

03/02/20 H.C. Wainwright
Forty Seven downgraded to Neutral from Buy at H.C. Wainwright
03/02/20 Roth Capital
Forty Seven downgraded to Neutral from Buy at Roth Capital
02/28/20 Benchmark
Ligand a 'coronavirus play in the making,' says Benchmark
Downgrade
Forty Seven downgraded to Neutral from Buy at Guggenheim » 10:18
03/03/20
03/03
10:18
03/03/20
10:18
FTSV

Forty Seven

$94.26 /

+0.38 (+0.40%)

Guggenheim analyst Etzer…

Guggenheim analyst Etzer Darout downgraded Forty Seven (FTSV) to Neutral from Buy following the company's announcement of an agreement to be acquired by Gilead (GILD).

ShowHide Related Items >><<
FTSV Forty Seven
$94.26 /

+0.38 (+0.40%)

03/03/20 Canaccord
Forty Seven downgraded to Hold from Buy at Canaccord
03/03/20 SunTrust
Forty Seven downgraded to Hold from Buy at SunTrust
03/03/20 Morgan Stanley
Forty Seven downgraded to Equal Weight from Overweight at Morgan Stanley
03/02/20 H.C. Wainwright
Forty Seven downgraded to Neutral from Buy at H.C. Wainwright
Downgrade
Forty Seven downgraded to Hold from Buy at Canaccord » 08:48
03/03/20
03/03
08:48
03/03/20
08:48
FTSV

Forty Seven

$93.88 /

+45.1 (+92.46%)

, GILD

Gilead

$75.40 /

+2.74 (+3.77%)

Canaccord analyst Arlinda…

Canaccord analyst Arlinda Lee downgraded Forty Seven to Hold from Buy following its announced acquisition by Gilead for $95.50 per share in cash.

ShowHide Related Items >><<
FTSV Forty Seven
$93.88 /

+45.1 (+92.46%)

03/03/20 SunTrust
Forty Seven downgraded to Hold from Buy at SunTrust
03/03/20 Morgan Stanley
Forty Seven downgraded to Equal Weight from Overweight at Morgan Stanley
03/02/20 H.C. Wainwright
Forty Seven downgraded to Neutral from Buy at H.C. Wainwright
03/02/20 JonesTrading
Forty Seven downgraded to Hold from Buy at JonesTrading
GILD Gilead
$75.40 /

+2.74 (+3.77%)

03/02/20 Roth Capital
Forty Seven downgraded to Neutral from Buy at Roth Capital
02/28/20 Benchmark
Ligand a 'coronavirus play in the making,' says Benchmark
02/28/20 Mizuho
Over 100% oncology buyout premiums suggestive of Forty Seven deal, says Mizuho
Downgrade
Forty Seven downgraded to Hold from Buy at SunTrust » 08:06
03/03/20
03/03
08:06
03/03/20
08:06
FTSV

Forty Seven

$93.88 /

+45.1 (+92.46%)

SunTrust analyst Asthika…

SunTrust analyst Asthika Goonewardene downgraded Forty Seven (FTSV) to Hold from Buy with a price target of $95.50, up from $55, following the company's confirmed acquisition by Gilead (GILD) at that price. The analyst believes that the deal is a good fit for Gilead and has already gone through a competitive bidding process, making it unlikely to be countered at this point.

ShowHide Related Items >><<
FTSV Forty Seven
$93.88 /

+45.1 (+92.46%)

03/03/20 Morgan Stanley
Forty Seven downgraded to Equal Weight from Overweight at Morgan Stanley
03/02/20 H.C. Wainwright
Forty Seven downgraded to Neutral from Buy at H.C. Wainwright
03/02/20 JonesTrading
Forty Seven downgraded to Hold from Buy at JonesTrading
03/02/20 Roth Capital
Forty Seven downgraded to Neutral from Buy at Roth Capital

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.